GlassScriptPhysician profile
Stephen J Webster
NPI 1922592617
$888.35
in general payments reported to CMS, 2019-2025
22 companies · $244 in 2025
The $244 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $106 · 2023: $211 · 2024: $327 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $136.67 | 2022-2025 | Ubrelvy |
| Boston Scientific Corporation | $79.06 | 2022-2025 | General - Pain Management |
| Medtronic, INC. | $76.26 | 2024 | Corevalve Evolut R, Venaseal, Symplicity G3 |
| Xeris Pharmaceuticals, INC. | $66.53 | 2025 | Recorlev |
| Novo Nordisk INC | $52.21 | 2022-2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $50.04 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $48.58 | 2023-2025 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $47.17 | 2023-2024 | |
| Tandem Diabetes Care, INC. | $47.07 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Inspire Medical Systems, INC. | $33.47 | 2025 | Inspire |
| Lilly USA, LLC | $31.48 | 2023-2024 | Mounjaro |
| Pfizer INC. | $30.13 | 2024 | |
| Electromed, INC. | $28.01 | 2024 | Smartvest |
| Hologic Sales and Service, LLC | $24.99 | 2023 | Aptima, Thinprep 2000 Processor |
| Exact Sciences Corporation | $21.75 | 2025 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $21.69 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.27 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.06 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.26 | 2022 | |
| Axsome Therapeutics, INC. | $14.03 | 2025 | Symbravo |
| Glaxosmithkline, LLC. | $13.12 | 2023 | Shingrix, Bexsero, Pediarix |
| Biohaven Pharmaceutical Holding Company LTD. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.